© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Drug costs
2021 Managed Healthcare Executive® Pharmacy Survey: What Federal Policy Will Most Likely Occur in 2021, Which Will Curb Drug Prices?
June 17, 2021
In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.
Is Competition the Way to Bring Down the Price of Diabetes Drugs?
June 07, 2021
Harvard researchers say, well, maybe.
Specialty Exceeds Traditional in Drug Spend
June 07, 2021
Ten years ago, specialty accounted for 15% to 20% of the money spent on drugs, according to Prem Shah, executive vice president of specialty pharmacy and product innovation at CVS Health.
Understanding the Economic Burden of Insomnia Treatment in Patients With Comorbid Conditions
May 04, 2021
Treating insomnia with commonly prescribed, older generation medications increases health care resource utilization and costs in patients with comorbid conditions.
Consumers Are Considering Prescription Changes and More Over High Drug Prices
April 16, 2021
A recent survey by Scripta Insights shows 96% of consumer are willing to make a prescription change as far as switching their medications, forms and where they fill in order to save money.
To Beat High Costs, California Moves to Create Its Own Drug Label
September 30, 2020
Patients With DME Who Switched to Eylea Had Better Vision After a Year
August 17, 2020
Real-world evidence from 67 patients recently found benefits for those with diabetic macular edema who switched to Eylea from Lucentis.
Real-World Data: Psoriatic Arthritis Patients Stay on Cosentyx After Other Options Fail
August 10, 2020
A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.
FDA Updates: Assays Used in Cancer Care Get Green Light
August 09, 2020
Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 09, 2020
In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.